Competing Causes of Death in Idiopathic Pulmonary Fibrosis.
作者信息
Thenappan Ashwatha, Maher Toby M, Yazbeck Leda, Jenkins R Gisli, Johnson Simon R, Stewart Iain, Oldham Justin M, Molyneaux Philip L
机构信息
Department of Internal Medicine.
Division of Pulmonary and Critical Care Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
出版信息
Am J Respir Crit Care Med. 2024 Oct 1;210(7):938-940. doi: 10.1164/rccm.202403-0595RL.
Abstract
摘要
相似文献
1
Competing Causes of Death in Idiopathic Pulmonary Fibrosis.特发性肺纤维化的竞争性死亡原因
Am J Respir Crit Care Med. 2024 Oct 1;210(7):938-940. doi: 10.1164/rccm.202403-0595RL.
2
Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century.21世纪特发性肺纤维化导致的全球死亡率不断上升。
Ann Am Thorac Soc. 2014 Oct;11(8):1176-85. doi: 10.1513/AnnalsATS.201404-145OC.
3
Underlying and immediate causes of death in patients with idiopathic pulmonary fibrosis.特发性肺纤维化患者的死亡根本原因和直接原因。
BMC Pulm Med. 2018 May 11;18(1):69. doi: 10.1186/s12890-018-0642-4.
4
Mortality Trends of Idiopathic Pulmonary Fibrosis in the United States From 2004 Through 2017.2004 年至 2017 年美国特发性肺纤维化的死亡率趋势。
Chest. 2021 Jan;159(1):228-238. doi: 10.1016/j.chest.2020.08.016. Epub 2020 Aug 14.
5
Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases.纤维化间质性肺疾病急性加重患者的预后和死亡原因。
BMJ Open Respir Res. 2020 Apr;7(1). doi: 10.1136/bmjresp-2020-000563.
6
Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.吡非尼酮可减少特发性肺纤维化患者与呼吸相关的住院次数。
Am J Respir Crit Care Med. 2017 Sep 15;196(6):756-761. doi: 10.1164/rccm.201701-0091OC.
7
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.吡非尼酮对死亡率的影响：特发性肺纤维化临床试验的汇总分析和荟萃分析。
Lancet Respir Med. 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. Epub 2016 Nov 19.
8
Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study.特发性肺纤维化的延迟就诊与生存：一项队列研究。
Am J Respir Crit Care Med. 2011 Oct 1;184(7):842-7. doi: 10.1164/rccm.201104-0668OC.
9
All-cause mortality of patients with idiopathic pulmonary fibrosis: a nationwide population-based cohort study in Korea.特发性肺纤维化患者的全因死亡率：韩国全国基于人群的队列研究。
Sci Rep. 2021 Jul 26;11(1):15145. doi: 10.1038/s41598-021-94655-x.
10
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化患者的 3 期临床试验。
N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18.
本文引用的文献
1
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.特发性肺纤维化（IPF）临床试验的有意义终点：强调“感觉、功能、生存”。在一次研讨会上的合作讨论报告，患者代表、研究者、美国国立卫生研究院、一个患者权益倡导组织和一个监管机构直接参与了此次研讨会。
Am J Respir Crit Care Med. 2024 Mar 15;209(6):647-669. doi: 10.1164/rccm.202312-2213SO.
2
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.特发性肺纤维化（更新版）和成人进展性肺纤维化：美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会临床实践指南。
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.
3
Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals.因果推断研究中的混杂因素控制与结果报告。呼吸、睡眠和重症监护期刊编辑给作者的指南。
Ann Am Thorac Soc. 2019 Jan;16(1):22-28. doi: 10.1513/AnnalsATS.201808-564PS.
4
Underlying and immediate causes of death in patients with idiopathic pulmonary fibrosis.特发性肺纤维化患者的死亡根本原因和直接原因。
BMC Pulm Med. 2018 May 11;18(1):69. doi: 10.1186/s12890-018-0642-4.
5
Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough.特发性肺纤维化试验中的数据缺失：不要让方法学问题破坏一项重大的治疗突破。
Eur Respir J. 2015 Sep;46(3):607-14. doi: 10.1183/13993003.02204-2014.
6
Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.吡非尼酮治疗特发性肺纤维化3期试验中用力肺活量变化的敏感性分析。
Chest. 2015 Jul;148(1):196-201. doi: 10.1378/chest.14-2817.
7
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.尼达尼布治疗特发性肺纤维化的疗效和安全性。
N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18.
8
PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery.特发性肺纤维化的特征分析：重新思考生物标志物的发现。
Eur Respir Rev. 2013 Jun 1;22(128):148-52. doi: 10.1183/09059180.00000913.
9
Clinical course and prediction of survival in idiopathic pulmonary fibrosis.特发性肺纤维化的临床病程和生存预测。
Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40. doi: 10.1164/rccm.201006-0894CI. Epub 2010 Oct 8.
10
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.用力肺活量呈边际下降与特发性肺纤维化的不良预后相关。
Eur Respir J. 2010 Apr;35(4):830-6. doi: 10.1183/09031936.00155108. Epub 2009 Oct 19.
Zotero 插件